Becton, Dickinson and Co. will invest more than $110M to expand a Nebraska syringe facility, add 120 jobs and support ...
The Medical segment of BD (Becton, Dickinson and Co.) focuses on solutions to reduce the spread of infection, enhance diabetes treatment, advance drug delivery, improve surgical procedures and more.
The move comes in response to increasing delivery demands for GLP-1s, plus broader conversations about pharmaceutical ...
The FDA cleared a pair of tests this week both aimed specifically at improving diagnoses of women’s health conditions. The tests came from BD and Visby Medical. Both are fast-turnaround PCR tests, and ...
BD (Becton, Dickinson and Company) was founded in 1897 by Maxwell Becton and Fairleigh Dickinson. For over 125 years, BD has ...
Under the transaction terms, BD shareholders received one share of Embecta stock for every five shares of BD that they held as of March 22. The Embecta spinoff severs all financial ties to BD, which ...
Becton & Dickinson 'Is Well On Its Way To Achieving 2025 Commitments,' Analyst Optimistic On Outlook
On Thursday, BD (Becton, Dickinson and Company) (NYSE:BDX) reported second-quarter sales of $5.04 billion, up 4.6% year over year, in line with the consensus. “Second quarter performance reflects our ...
Becton, Dickinson and Company (referred hereon as BD) is a global medical device company with a diversified and high-quality portfolio. BD's three main segments, BD Medical, BD Life Sciences, and BD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results